Connect with us

Business

LSD Treatments for Alzheimer’s Ramps Up with New Research from the Beckley Foundation

Published

on

Could psychedelics hold the key to solving the Alzheimer epidemic?

The requirement for the much-needed boost in the use of LSD for medicinal reasons has always been increase in clinical research and it seems that’s about to improve. Recent news that LSD research for Alzheimer’s was about to kickstart through the Beckley Foundation is certainly being welcomed fully. There are certainly still some kinks and nuts to work out before we can see the effect come to light but it’s a good place to start. Read on as we shed light on the important things to consider as the studies are set to commence as soon as possible.

Beckley Foundation and LSD Studies

The founder of the foundation, Amanda Feilding has recently announced that the organization is set to begin a special research program for LSD. For those in the world of psychedelics and are conversant with the Beckley Foundation, its recent announcement would not have come as a surprise. The new research program will be in collaboration with King’s College London and UCL. The basis of the research program will be centred on the effects of the full dose of LSD on the brain. Another breakout study that the foundation will be taking on is the effects of microdosing LSD for Alzheimer’s disease. It’s reported that this study will be carried out with the University of Basel.

Since its creation in 1998, the Beckley Foundation has been at the forefront of global drug policy reforms and research on psychoactive substances. This has given the foundation a wide reach as an UN-accredited NGO gradually pushing for reform policies and backing it up with different streams of clinical research. The new set of studies on LSD is set to follow in that light of quality studies being embarked on by the foundation to advocate for policy reforms and harness the benefits of these psychoactive substances. 

Research on the Effects of LSD

The first study by the firm will see to understand the full scope of the effects of LSD on the brain and the concurrent changes that ensue. Many have characterized this as a mystical experience and this is what the initial study will seek to explore. This will serve as the basis for understanding and promoting the growth of psychedelic-assisted therapy. Exploration of the profound sense of connection the user feels in relation to the brain changes seen can very well be the solution to previous inquiries.

This novel study can also break the walls of what is known and what is not known in the neurobiology of consciousness. This makes the collaboration between Fielding and the neuroimaging expert of King’s College London and UCL very cogent and timely. The latest neuroimaging technology is set to be used by the researchers in the analysis. It is therefore expected that every important detail will be monitored thoroughly and expatiated fully. Therefore, there is no doubt significant brain changes that could be inspirational to understanding the effects of LSD on the brain will be identified and understood.

Research on Effects of Microdosing LSD for Alzheimer’s Disease

Physicians from the University of Basel are set to collaborate with Fielding on the second novel study embarked upon by the Beckley Foundation. The study is set to examine the therapeutic effects of microdosing LSD for the treatment of some symptoms in patients with Alzheimer’s disease. The major symptoms of focus are apathy and depression which is common with patients suffering from Alzheimer’s disease and other forms of neurodegenerative conditions. The research is bound to be monumental as its findings could serve as the basis for other concurrent studies on the subject matter.

A less pronounced third study is also being carried out by the Beckley Foundation in conjunction with Cornell University. The basis of the research is centred on understanding how LSD affects blood circulation in the body and also the influence of neurons on this circulation. The research is set to be done using advanced optical imaging which is expected to give a great deal of precision and accuracy to the expected results. The combination of these three projects shows a multi-armed research project being put forward by the Beckley foundation while maximizing the latest benefits of improved neuroimaging technologies.          

Amanda Fielding – A Voice For Psychedelics

We stated earlier that those who are conversant with the world of psychedelics already know who Amanda Fielding is and what the Beckley Foundation stands for. Well, for those who do not know Fielding is commonly referred to as the “Queen of Psychedelics”. She did not just come about this name by accident, it is a product of much work in the world of psychedelic research. She was just recently given the Science Pioneer Award for Women’s Entrepreneurship Day Organization. This award is significant because it is the first time the award is given to a leading psychedelic researcher.   

Feilding has coauthored several peer-reviewed studies on psychedelics and has also been in the company of quality psychedelic pioneers. With names like Albert Hofmann, Terrence McKenna, Sash and Ann Shulgin and many others as thought partners, it is no wonder she has gotten such accolades. Under her leadership, the foundation has collaborated with top scientists and institutions across the world on different types of psychoactive substances. The list of her research projects is long which includes assessing the effects of cannabis, LSD, ayahuasca, psilocybin, DMT, and MDMA. 

Bottom line

Fielding and Beckley Foundation are not holding back on their moves for the studies on LSD and in no time, extensive  works of research will begin and results will troop in. Many are anticipating favourable results from these studies as they could mean a new lifeline for patients living with Alzheimer’s disease. This could see us harnessing the medicinal benefits of LSD either at its full dose or through microdosing. More research on LSD is also expected to follow through after this set of studies and this can only be good news for those who see the potential of LSD.

Source: https://cannabis.net/blog/news/lsd-treatments-for-alzheimers-ramps-up-with-new-research-from-the-beckley-foundation

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News